In the article “Amyloid Reduction by Amyloid-β Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease” by Donna M. Wilcock, Nastaran Gharkholonarehe, William E. Van Nostrand, Judianne Davis, Michael P. Vitek, and Carol A. Colton, which appeared on pages 7957–7965 of the June 24, 2009 issue, there were errors in Figures 2 and 5. The immunocytochemical photomicrographs of NeuN in Figures 2 and 5 were designed to be representative of the quantitative data presented in the paper. However, incorrect higher magnification panels were inserted in both figures. Corrected higher magnification views (G, H) are presented here. The conclusions in the published study were not affected by the figure errors. Clear and statistically significant neuronal loss is observed in KLH-vaccinated (control) mice of both bigenic strains, while Abeta42 vaccination of both bigenic strains produced less neuronal loss compared to their KLH- treated counterparts (i.e., is protective). The correct versions of Figures 2 and 5 and their legends appear below.
Tau pathology and neuron loss are reduced in APPSwDI/NOS2−/− mice receiving Aβ42 vaccination. A, B, AT8 immunohistochemistry in the cerebral cortex of APPSwDI/NOS2−/− mice receiving either KLH vaccination (control) (A) or Aβ42 vaccination (B) is shown. Magnification, 200×; scale bar, 25mm. (C) Representative western blots for AT8, AT180, and tau 5 from APPSwDI/NOS2−/− mice receiving KLH (control) or Aβ42 vaccination (Vacc) are shown. D, The average ratio of band intensity normalized to total tau (+SEM) from AT8 and AT180 western blots is shown (n = 7 mice receiving KLH vaccination and n = 8 receiving Aβ42 vaccination). E–H, NeuN immunohistochemistry in the hippocampus (E and F: magnification, 40×; scale bar, 120mm) and CA3 (G and H: magnification, 200×; scale bar, 25mm) of APPSwDI/NOS2−/− mice receiving either KLH (control) (E and G) or Aβ42 (F and H) vaccination is shown. Dotted boxes in E and F indicate the region shown at higher magnification in G and H, respectively. Representative Nissl stained sections from APPSwDI/NOS2−/− KLH (control) (I) or Aβ42 vaccinated mice (J). Magnification, 40×. Note: sections are from different mice than those shown in E and F. K, Stereological counts of the CA3 region of NOS2−/−, APPSwDI/NOS2−/− KLH (control), and APPSwDI/NOS2−/− mice receiving Aβ42 vaccination are shown. p < 0.05; p < 0.01 compared to NOS2−/− mice.
Tau pathology and neuron loss are reduced in APPSw/NOS2−/− mice receiving Aβ42 vaccination. A, B, AT8 immunohistochemistry in the cerebral cortex of APPSw/NOS2−/− mice receiving either KLH vaccination (control) (A) or Aβ42 vaccination (B) is shown. Magnification, 100×; scale bar, 50mm. C, Representative western blots for AT8, AT180, and tau 5 from APPSw/NOS2−/− mice receiving KLH (control) or Aβ42 vaccination (Vacc) are shown. D, Mean densitometry data of AT8 and AT180 western blots, normalized to total tau levels, are shown. N = 5 mice receiving KLH vaccination and N = 5 receiving Aβ42 vaccination. E–H, NeuN immunohistochemistry in the hippocampus (E and F: magnification, 40×) and CA3 (G and H: magnification, 200×) of APPSw/NOS2−/− mice receiving either KLH (E and G) or Aβ42 (F and H) vaccination are shown. Dotted boxes in E and F indicate the region shown at higher magnification in G and H. Representative Nissl-stained sections from APPSw/NOS2−/− KLH (control) (I) or Aβ42-vaccinated mice (J). Magnification, 40×. Note: Sections are from different mice than those shown in E and F. K shows stereological counts of the CA3 region of NOS2−/−, APPSw/NOS2−/− KLH (control), and APPSw/NOS2−/− mice receiving Aβ vaccination. *, p < 0.05, **, p < 0.01 compared to NOS2−/− mice.